Discovery on Target: Cambridge Healthtech Institute’s 18th Annual Target Identification and Validation, Proteomics-Based Target Discovery
Boston, MA and Virtual
Atomic-Resolution Prediction of Degrader-mediated Ternary Complex Structures by Combining Molecular Simulations with HDX-MSJesus Izaguirre, PhD, Senior Director Advanced Simulations, Roivant Sciences Inc.
Design & Development of a Systemic, Small Molecule STING Agonist: Tailoring Drug Properties and Dosing Paradigm to Optimize Therapeutic Index for the Treatment of Cancer PatientsChristopher Winter, Ph.D., chief of research & development
Cambridge Healthtech Institute’s 16th Annual Drug Discovery Chemistry: Optimizing Small Molecules for Tomorrow’s Therapeutics Including COVID
Virtual
From Physics to Clinic: Design of a Novel Small Molecule STING Agonist (SNX281) with Excellent Drug Properties and Systemic DeliveryWoody Sherman, Ph.D., chief scientific officer
Precision In Drug Discovery & Preclinical Virtual Summit (West Coast)
Virtual
Woody Sherman, Ph.D., chief scientific officer
LifeSci Cloud Chat Q1’21
Virtual
Vipin Sachdeva, Ph.D., director, head of high-performance computing
Precision in Drug Discovery & Preclinical Virtual Summit East